Tectonic Therapeutic Inc. Common Stock (TECX)
Stock · NASDAQ · Health Care
$20.65as of 10/16/2026
Price chart
Active signals
TECX Signal Track Record
How signals performed across all stocks →What TECX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +2.4% | 59% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +2.6% | 52% | August 12, 2026 |
| Bollinger Band Breakdown | 17 | +3.4% | 53% | April 21, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +3.3% | 85% | September 16, 2026 |
| Any 20-session window (baseline) | +1.6% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TECX
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPC…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 60
- Website
- tectonictx.com/
Fundamentals
- 1-day range
- $22.6$23.66
- Market cap
- $570.23M
- P/E (trailing)
- —
- P/E (forward)
- -4.98
- EPS (trailing)
- $-4.56
- Dividend yield
- —
- Beta
- 1.29
- Avg. volume
- 222.9K
Forecasts
8 analyst ratings
Tectonic Therapeutic Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TECXTectonic Therapeutic Inc. Common Stock$20.65▼ 3.05%Market cap $570.23MP/E —$14.6$39.53
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- RGNXREGENXBIO Inc. Common Stock$6.93▼ 3.28%Market cap $583.15MP/E —$5.46$16.19
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $20.65 | ▼ 3.05% | $14.6$39.53 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| RGNX REGENXBIO Inc. Common Stock | $583.15M | — | $6.93 | ▼ 3.28% | $5.46$16.19 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Peter McNamara · September 30, 2026 · Sale536 @ $23.04
- Marcella K. Ruddy · September 25, 2026 · Tax Withholding525 @ $23.67
- Peter McNamara · September 25, 2026 · Tax Withholding444 @ $23.67
- Marc Schwabish · September 25, 2026 · Tax Withholding411 @ $23.67
- Daniel Lochner · September 25, 2026 · Tax Withholding520 @ $23.67
- Alise Reicin · September 25, 2026 · Tax Withholding1.5K @ $23.67
- Marcella K. Ruddy · September 3, 2026 · Grant24.3K
- Peter McNamara · September 3, 2026 · Grant21.0K
- Marc Schwabish · September 3, 2026 · Grant17.8K
- Daniel Lochner · September 3, 2026 · Grant24.3K
- Alise Reicin · September 3, 2026 · Grant69.3K
- Peter McNamara · August 25, 2026 · Sale43 @ $36.52
- Peter McNamara · August 25, 2026 · Option Exercise43 @ $14.71
- Peter McNamara · August 12, 2026 · Option Exercise43 @ $14.71
- Peter McNamara · August 12, 2026 · Sale43 @ $35
Institutional Ownership
March 31, 2026
- Total shares held
- 13.96M
- Total value held
- $416.45M
- Institutional holders
- 108
- Unknown2.82M
- Unknown1.20M
- Unknown1.14M
- Unknown860.4K
- Unknown847.2K
- Unknown647.7K
- Unknown607.8K
- Unknown606.7K
- Unknown473.5K
- Unknown328.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
TECX Reports Positive Phase 1 Data for TX2100 in HHT
Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.
TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.